Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

Protocol No
ALLIANCE-A032002-ART
Principal Investigator
Ariel Nelson
Phase
II
Summary
This study is being done to answer the following question: Does adding radiation therapy to immunotherapy decrease the growth or spread of urothelial cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your urothelial cancer. The usual approach is defined as care most people get for urothelial cancer.
Description
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL